Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 195

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung

Miyoshi, Tomohiro, Umemura, Shigeki, Matsumura, Yuki, Mimaki, Sachiyo, Tada, Satoshi, Makinoshima, Hideki, Ishii, Genichiro, Udagawa, Hibiki, Matsumoto, Shingo, Yoh, Kiyotaka, Niho, Seiji, Ohmatsu, Hironobu, Aokage, Keiju, Hishida, Tomoyuki, Yoshida, Junji, Nagai, Kanji, Goto, Koichi, Tsuboi, Masahiro, Tsuchihara, Katsuya · 2017 · Clinical Cancer Research

Abstract

Purpose: Although large-cell neuroendocrine carcinoma (LCNEC) of the lung shares many clinical characteristics with small-cell lung cancer (SCLC), little is known about its molecular features. We analyzed lung LCNECs to identify biologically relevant genomic alterations. Experimental Design: We performed targeted capture sequencing of all the coding exons of 244 cancer-related genes on 78 LCNEC samples [65 surgically resected cases, including 10 LCNECs combined with non–small cell lung cancer (NSCLC) types analyzed separately, and biopsies of 13 advanced cases]. Frequencies of genetic alterations were compared with those of 141 SCLCs (50 surgically resected cases and biopsies of 91 advanced cases). Results: We found a relatively high prevalence of inactivating mutations in TP53 (71%) and RB1 (26%), but the mutation frequency in RB1 was lower than that in SCLCs (40%, P = 0.039). In addition, genetic alterations in the PI3K/AKT/mTOR pathway were detected in 12 (15%) of the tumors: PIK3CA 3%, PTEN 4%, AKT2 4%, RICTOR 5%, and mTOR 1%. Other activating alterations were detected in KRAS (6%), FGFR1 (5%), KIT (4%), ERBB2 (4%), HRAS (1%), and EGFR (1%). Five of 10 cases of LCNECs combined with NSCLCs harbored previously reported driver gene alterations, all of which were shared between the two components. The median concordance rate of candidate somatic mutations between the two components was 71% (range, 60%–100%). Conclusions: LCNECs have a similar genomic profile to SCLC, including promising therapeutic targets, such as the PI3K/AKT/mTOR pathway and other gene alterations. Sequencing-based molecular profiling is warranted in LCNEC for targeted therapies. Clin Cancer Res; 23(3); 757–65. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-0355

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 195

Metadata

Authors
Miyoshi, T., Umemura, S., Matsumura, Y., Mimaki, S., Tada, S., Makinoshima, H., Ishii, G., Udagawa, H., Matsumoto, S., Yoh, K., Niho, S., Ohmatsu, H., Aokage, K., Hishida, T., Yoshida, J., Nagai, K., Goto, K., Tsuboi, M., & Tsuchihara, K.
Venue
Clinical Cancer Research
Published
2017-01-31
Volume
23
Issue
3
Pages
757-765
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2484492934
Cited by
195
References
4
FWCI
10.33
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0355
The paper
Miyoshi, T., Umemura, S., Matsumura, Y., Mimaki, S., Tada, S., Makinoshima, H., Ishii, G., Udagawa, H., Matsumoto, S., Yoh, K., Niho, S., Ohmatsu, H., Aokage, K., Hishida, T., Yoshida, J., Nagai, K., Goto, K., Tsuboi, M., & Tsuchihara, K. (2017). Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0355

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.